CD19 and lymphoma: In another recent study by Stein-Thoeringer et al., a large cohort of lymphoma patients receiving second-generation CD19 CAR-T cells (122 were treated with axicabtagene ciloleucel (axi-cel), 49 received tisagenlecleucel (tisa-cel) and 1 received lisocabtagene maraleucel (liso-cel)) in Germany and the U.S. were established (112).